Compass Pathways Launches Change the Tune in TRD
LONDON and NEW YORK — September 15, 2026 Compass Pathways plc announced the launch of Change the Tune in...
Treatment-Resistant Depression
Advertisement
NRx Pharmaceuticals Deploys Robotic TMS Across HOPE Clinics
WILMINGTON, Del. — September 11, 2026 NRx Pharmaceuticals, Inc. announced that its subsidiary HOPE Therapeutics has begun training and...
Compass Pathways Names U.S. Grant Recipients for COMP360 Training
LONDON and NEW YORK — September 10, 2026 Compass Pathways plc announced that five organizations have been awarded grants...
EPIK Biosciences Expands Ketamine and DXM Drug Portfolio
AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...
Compass Pathways Advances COMP360 Toward Potential TRD Launch
LONDON and NEW YORK — September 9, 2026 Compass Pathways plc announced positive topline 52-week open-label results from Part...
Advertisements
Johnson & Johnson Highlights New Neuropsychiatry Data
Titusville, New Jersey, U.S., September 8, 2026 Johnson & Johnson is set to present new clinical and real-world evidence...
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Lilly Acquires AtaiBeckley to Advance Depression Therapies
INDIANAPOLIS and NEW YORK, July 16, 2026 Eli Lilly and Company has announced a definitive agreement to acquire AtaiBeckley...
AtaiBeckley Completes Patient Dosing in Phase 2b VLS-01 TRD Trial
NEW YORK, July 6, 2026 AtaiBeckley Inc. announced that the final patient has been dosed in Elumina, its international...
Optimi Health Launches Standardized Psilocybin Microdose Capsules for Clinical Research
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
Advertisement
